CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity

Uri Greenbaum(Ben-Gurion University of the Negev), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Raphaël Steiner(The University of Texas MD Anderson Cancer Center), Fevzi Yalniz, Gabriela Rondón(The University of Texas MD Anderson Cancer Center), Maria Alma Rodriguez(The University of Texas MD Anderson Cancer Center), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Jeremy Ramdial(The University of Texas MD Anderson Cancer Center), Janet Rodríguez‐Torres, Hun Ju Lee(The University of Texas MD Anderson Cancer Center), Simrit Parmar(The University of Texas MD Anderson Cancer Center), Swaminathan P. Iyer(The University of Texas MD Anderson Cancer Center), Luis Fayad(The University of Texas MD Anderson Cancer Center), Yago Nieto(The University of Texas MD Anderson Cancer Center), Misha Hawkins(The University of Texas MD Anderson Cancer Center), Sudhakar Tummala(The University of Texas MD Anderson Cancer Center), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Paolo Strati(The University of Texas MD Anderson Cancer Center), Samer A. Srour(The University of Texas MD Anderson Cancer Center), Richard E. Champlin(The University of Texas MD Anderson Cancer Center), Chitra Hosing(The University of Texas MD Anderson Cancer Center), Elizabeth J. Shpall(Scripps MD Anderson Cancer Center), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Partow Kebriaei(The University of Texas MD Anderson Cancer Center), Felipe Samaniego(The University of Texas MD Anderson Cancer Center), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Michael Wang(St. Joseph Health System), Ranjit Nair(NewYork–Presbyterian Brooklyn Methodist Hospital), Katayoun Rezvani(The University of Texas MD Anderson Cancer Center), Rima M. Saliba, Chelsea C. Pinnix(The University of Texas MD Anderson Cancer Center)
Blood Advances
July 15, 2021
10.1182/bloodadvances.2021004575
Cited by 146

Related Papers

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
|Blood|1997|1.2k
2016 US lymphoid malignancy statistics by World Health Organization subtypes
|CA A Cancer Journal for Clinicians|2016|1.1k
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
|Journal of Clinical Oncology|1998|927